Cristina Oprean

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

Véronique Dièras, Hyo S. Han, Bella Kaufman et al. · The Lancet Oncology · 2020 · 321 citations · Full text

Medicine, Oncology, Pharmacology +10

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Matti Aapro, H. S. Rugo, Giada Rizzi et al. · Annals of Oncology · 2014 · 248 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone et al. · Journal of Thoracic Oncology · 2021 · 202 citations

Medicine, Oncology, Pharmacology +13

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Jérôme Fayette, Lori J. Wirth, Cristina Oprean et al. · Frontiers in Oncology · 2016 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Matti Aapro, Meinolf Karthaus, Lee S. Schwartzberg et al. · Supportive Care in Cancer · 2016 · 48 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17